Astrazeneca Ab

Dainippon Sumitomo Pharma Co., Ltd.

Anna-Karin Tidén

Yvonne Lo-Alfredsson

Donald Pivonka

Anders Bogevig

Stephen Thom

Thomas McInally

Gunnar Nordvall

Nicholas James Bennett

Jenny Viklund

Tobias Mochel

Sverker Hanson

Anders Bögevig

Donald Astrazeneca Wilmington Pivonka

There are disclosed novel compounds of formula (I) wherein R, R, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.

Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy

The present invention provides compounds of formula (I) wherein R, R, Rand Rare as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers

There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R, R, R, R, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.

Thioxanthine derivatives as myeloperoxidase inhibitors

There are disclosed novel compounds of Formula (I) wherein L, R, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders. 

Thioxanthine derivatives and their use as inhibitors of MPO

The present invention relates to a compound according to Formula (I) whereinRis selected from C-Calkyl, and said C-Calkyl is substituted with C-Calkoxy; and at least one of said C-Calkyl or said C-Calkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.

2 thioxanthine derivatives acting as MPO-inhibitors

There are disclosed novel compounds of formula (I) wherein R, R, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders. 

Growing community of inventors

Södertälje, Sweden

Anna-Karin Tidén